CEBP CTRC-AACR San Antonio Breast Cancer Symposium Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hou, S.-M.
Right arrow Articles by Lambert, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hou, S.-M.
Right arrow Articles by Lambert, B.
Cancer Epidemiology Biomarkers & Prevention Vol. 10, 133-140, February 2001
© 2001 American Association for Cancer Research

Differential Interactions between GSTM1 and NAT2 Genotypes on Aromatic DNA Adduct Level and HPRT Mutant Frequency in Lung Cancer Patients and Population Controls1

Sai-Mei Hou2, Susann Fält, Ke Yang, Fredrik Nyberg, Göran Pershagen, Kari Hemminki and Bo Lambert

Environmental Medicine Unit (S-M. H., S. F., B. L.) and Molecular Epidemiology Unit (K. Y., K. H.), Department of Biosciences, The Karolinska Institute, S-141 57 Huddinge Sweden, and Division of Environmental Epidemiology (F. N., G. P.), Institute of Environmental Medicine at the Karolinska Institute, S-171 77 Stockholm, Sweden

We have studied the influence of GSTM1 and NAT2 genotypes on aromatic DNA adduct level (AL) and HPRT mutant frequency (MF) in smokers with newly diagnosed lung cancer and matched population controls. AL was analyzed in relation to genotypes in 170 cases and 144 controls (113 current/recent smokers and 201 former/never smokers), and MF in 157 cases and 152 controls (155 ever smokers and 154 never smokers). Both genotypes exhibited the a priori expected effects on AL and MF among controls only, especially among smoking controls [significantly lower pack-years (a pack-year is defined as 1 pack of cigarettes/day for 1 year) than among cases]. Among the 42 currently smoking controls, the NAT2 slow genotype [odds ratio (OR), 7.5; 95% confidence interval (CI), 1.5–38.4], in particular in combination with the GSTM1 null genotype (OR, 19.3, 95% CI, 1.1–338.6 for null/slow versus positive/rapid) was strongly associated with high AL. The null/slow combination was also significantly associated with high MF among ever smokers (cases and controls pooled) with lower pack-years (OR, 3.7; 95% CI, 1.3–10.7 versus all of the other genotypes; OR, 5.1; 95% CI, 1.2–22.4 versus positive/rapid). In contrast, an antagonistic gene-gene interaction was seen among smoking cases for both AL and MF. Only currently smoking cases with the combined GSTM1 null and NAT2 rapid genotype showed a positive correlation between lnAL and lnMF (r, 0.64; P = 0.1), and an increase of AL with both age and daily cigarette use. This genotype combination was also associated with high MF among ever-smoking cases (OR, 4.0; 95% CI, 0.9–17.7 versus positive/rapid). There was a significant interaction between NAT2 genotype and pack-years of smoking among cases, so that the rapid genotype was associated with high MF among ever-smoking cases diagnosed at higher pack-years, whereas the slow genotype was associated with high MF at lower pack-years. These findings suggest that the influence of NAT2 genotype on AL and MF and its interaction with GSTM1 genotype may be dose dependent. The NAT2 slow genotype, in particular when combined with the GSTM1 null genotype, may confer increased susceptibility to adduct formation, gene mutation, and lung cancer when the smoking dose is low.




This article has been cited by other articles:


Home page
Am J EpidemiolHome page
C. Carlsten, G. S. Sagoo, A. J. Frodsham, W. Burke, and J. P. T. Higgins
Glutathione S-Transferase M1 (GSTM1) Polymorphisms and Lung Cancer: A Literature-based Systematic HuGE Review and Meta-Analysis
Am. J. Epidemiol., April 1, 2008; 167(7): 759 - 774.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
H. E. Liu, P.-Y. Hsiao, C.-C. Lee, J.-A. Lee, and H.-Y. Chen
NAT2*7 Allele Is a Potential Risk Factor for Adult Brain Tumors in Taiwanese Population
Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 661 - 665.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
A. G. Schwartz, G. M. Prysak, C. H. Bock, and M. L. Cote
The molecular epidemiology of lung cancer
Carcinogenesis, March 1, 2007; 28(3): 507 - 518.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
T. Kohno, T. Sakiyama, H. Kunitoh, K. Goto, Y. Nishiwaki, D. Saito, H. Hirose, T. Eguchi, N. Yanagitani, R. Saito, et al.
Association of polymorphisms in the MTH1 gene with small cell lung carcinoma risk
Carcinogenesis, December 1, 2006; 27(12): 2448 - 2454.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
P. Wallstrom, K. Frenkel, E. Wirfalt, B. Gullberg, J. Karkoszka, J. Seidegard, L. Janzon, and G. Berglund
Antibodies against 5-Hydroxymethyl-2'-deoxyuridine Are Associated with Lifestyle Factors and GSTM1 Genotype: A Report from the Malmo Diet and Cancer Cohort
Cancer Epidemiol. Biomarkers Prev., May 1, 2003; 12(5): 444 - 451.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
F. Nyberg, S.-M. Hou, G. Pershagen, and B. Lambert
Dietary fruit and vegetables protect against somatic mutation in vivo, but low or high intake of carotenoids does not
Carcinogenesis, April 1, 2003; 24(4): 689 - 696.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
K. Alexandrov, I. Cascorbi, M. Rojas, G. Bouvier, E. Kriek, and H. Bartsch
CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation
Carcinogenesis, December 1, 2002; 23(12): 1969 - 1977.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
D. H. Phillips
Smoking-related DNA and protein adducts in human tissues
Carcinogenesis, December 1, 2002; 23(12): 1979 - 2004.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. D. Hunt, A. Strimas, J. E. Martin, M. Eyer, M. Haddican, B. G. Luckett, B. Ruiz, T. W. Axelrad, W. L. Backes, and E. T. H. Fontham
Differences in KRAS Mutation Spectrum in Lung Cancer Cases between African Americans and Caucasians after Occupational or Environmental Exposure to Known Carcinogens
Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1405 - 1412.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
G E Goodman
Lung cancer * 1: Prevention of lung cancer
Thorax, November 1, 2002; 57(11): 994 - 999.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
S.-M. Hou, S. Falt, S. Angelini, K. Yang, F. Nyberg, B. Lambert, and K. Hemminki
The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk
Carcinogenesis, April 1, 2002; 23(4): 599 - 603.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2001 by the American Association for Cancer Research.